Post Infusion

The transfer of genetically engineered lymphocytes in melanoma patients: a Phase I dose escalation study
Courtney Regan, Michael Nishimura, I Caroline Le Poole, Constantine Godellas, Patrick Stiff, Elizabeth Garrett-Mayer, Mingli Li, Keisuke Shirai, Jonathan Eby, Heather Embree, Boro Dropulic, Ann Lau Clark, Kelli Hutchens, Joseph I Clark

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P168; DOI: 10.1186/2051-1426-3-S2-P168
Deep phenotypic characterization of NY-ESO TCR engineered T cells and tumor in patients with advanced myeloma
Eduardo Davila, Luca Melchiori, Ryan Wong, Gwendolyn Binder-Scholl, Rafael Amado, Bent Jakobsen, Aaron Rapoport

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P295; DOI: 10.1186/2051-1426-3-S2-P295
First generation anti-CD19 chimeric antigen receptor-modified T cells for management of B cell malignances: initial analysis of an ongoing Phase I clinical trial
Manon Evans, Ryan Guest, Dominic Rothwell, Debbie Burt, Natalia Kirillova, Jennifer Haughton, Shien Chow, Fiona Thistlethwaite, David Gilham, Robert Hawkins

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P12; DOI: 10.1186/2051-1426-2-S3-P12

Main menu